# Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

> **NCT04957758** · PHASE2 · COMPLETED · sponsor: **Oyster Point Pharma, Inc.** · enrollment: 113 (actual)

## Conditions studied

- Neurotrophic Keratopathy

## Interventions

- **DRUG:** OC-01 (varenicline) nasal spray 1.2 mg/ml
- **DRUG:** Placebo (vehicle) nasal spray

## Key facts

- **NCT ID:** NCT04957758
- **Lead sponsor:** Oyster Point Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-17
- **Primary completion:** 2023-01-27
- **Final completion:** 2023-04-28
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04957758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04957758, "Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04957758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*